United States · FDA National Drug Code directory
DILTIAZEM HCI
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 51662-1457_132cd9f9-a36c-4e35-e063-6294a90aaa17
- Product NDC
- 51662-1457
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- DILTIAZEM HCI
- Labeler
- HF Acquisition Co LLC, DBA HealthFirst
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20191215
- Source listing expiry
- 20261231
Source-listed ingredients
- DILTIAZEM HYDROCHLORIDE — 100 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (51662-1457-1) · 51662-1457-1
- 10 POUCH in 1 CASE (51662-1457-3) / 1 VIAL, PATENT DELIVERY SYSTEM in 1 POUCH (51662-1457-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM · 51662-1457-3
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →